Article
Primary systemic anaplastic large-cell lymphoma (CD30+): advances in biology and current therapeutic approaches.
Clinical lymphoma - 1 Jun 2001
Fiorani C, Vinci G, Sacchi S, Bonaccorsi G, Artusi T
Abstract excerpt
In 1985, Stein et al demonstrated the expression of the lymphoid activation antigen CD30/Ki by neoplastic cells. Fifteen years after the first description, anaplastic large-cell lymphomas (ALCL) are now thought to be a heterogeneous group in terms of their clinical, morphologic, phenotypic, cytogenetic, and molecular biology features. However, on the basis of a specific genetic anomaly and expression of a...
Topics
- Age Factors
- Anaplastic Lymphoma Kinase
- Biomarkers, Tumor
- Clinical Trials as Topic
- Gene Expression Regulation, Neoplastic
- Humans
- Lymphoma, Large B-Cell, Diffuse
- Phenotype
- Prognosis
- Protein-Tyrosine Kinases
- Receptor Protein-Tyrosine Kinases
- Translocation, Genetic